Company intelligence / Profile preview

Healthy Star Bio-Tech R&D

Hong Kong, Hong Kong, China

Ownership: Private
Development stage: Other

Overview

Healthy Star is a clinical-stage biotechnology company focused on the research and development of innovative small molecule therapeutics for metabolic diseases. The company's lead programs target Type 2 diabetes through novel mechanisms, including GPR119 agonism and SGLT2 inhibition. Healthy Star operates primarily out of Hong Kong and mainland China, leveraging a specialized R&D team to advance its pipeline through early-stage clinical trials. Its business model centers on the discovery of high-potential drug candidates for licensing or co-development within the global pharmaceutical market.

Therapeutic areas: EndocrinologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Healthy Star Bio-Tech R&D.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Healthy Star Bio-Tech R&D.

Explore the full profile